SARS-CoV-2 genomic characterization and clinical manifestation of

the COVID-19 outbreak in Uruguay

Victoria Elizondo[1]*,[#], Gordon W. Harkins[2,#], Batsirai Mabvakure[3,#], Sabine

Smidt[2], Paul Zappile[4], Christian Marier[4], Matthew Maurano[5], Victoria

Perez[1,6], Natalia Mazza[1], Carolina Beloso[1,7], Silvana Ifran[1], Mariana

Fernandez[1], Andrea Santini[1], Veronica Perez[1], Veronica Estevez[1], Matilde

Nin[1], Gonzalo Manrique[1], Leticia Perez[1], Fabiana Ross[1], Susana Boschi[1],

Maria Noel Zubillaga[1], Raquel Balleste[1], Simon Dellicour[8,9], Adriana

Heguy[4,5,]*, Ralf Duerr[5,]*.

[1] Laboratorio de Biología Molecular, Asociación Española Primera en Salud,

Montevideo, Uruguay

[2] South African Medical Research Council Capacity Development Unit, South African

National Bioinformatics Institute, University of the Western Cape, Bellville, South

Africa

[3] Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland,

United States of America

[4] Genome Technology Center, Office for Science and Research, NYU Langone Health,

New York, New York, United States of America

[5] Department of Pathology, NYU Grossman School of Medicine, New York, New York,

United States of America

6 Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de

Medicina, Udelar, Montevideo, Uruguay

7 Departamento de Biodiversidad y Genética. Instituto de Investigaciones Biológicas

Clemente Estable, Montevideo, Uruguay

8 Spatial Epidemiology Lab. (SpELL), Université Libre de Bruxelles, Bruxelles, Belgium

9 Department of Microbiology, Immunology and Transplantation, Rega Institute,

Leuven, Belgium

 # Shared first authors

* Corresponding authors

Victoria Elizondo, Ph.D.   E-mail: totiep@gmail.com

Adriana Heguy, Ph.D.   E-mail: Adriana.Heguy@nyulangone.org

Ralf Duerr, MD, Ph.D.   E-mail: Ralf.Duerr@nyulangone.org

SARS-CoV-2 genomic characterization and clinical manifestation of

the COVID-19 outbreak in Uruguay

Abstract

COVID-19 is a respiratory illness caused by severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) and declared by the World Health Organization as a

global public health emergency. Among the severe outbreaks across South America,

Uruguay has become known for curtailing SARS-CoV-2 exceptionally well. To

understand the SARS-CoV-2 introductions, local transmissions, and associations with

genomic and clinical parameters in Uruguay, we sequenced the viral genomes of 44

outpatients and inpatients in a private healthcare system in its capital, Montevideo, from

March to May 2020. We performed a phylogeographic analysis using sequences from

our cohort and other studies that indicate a minimum of 23 independent introductions

into Uruguay, resulting in five major transmission clusters. Our data suggest that most

introductions resulting in chains of transmission originate from other South American

countries, with the earliest seeding of the virus in late February 2020, weeks before the

borders were closed to all non-citizens and a partial lockdown implemented. Genetic

analyses suggest a dominance of S and G clades (G, GH, GR) that make up >90% of the

viral strains in our study. In our cohort, lethal outcome of SARS-CoV-2 infection

significantly correlated with arterial hypertension, kidney failure, and ICU admission

(FDR < 0.01), but not with any mutation in a structural or non-structural protein, such

as the spike D614G mutation. Our study contributes genetic, phylodynamic, and clinical

correlation data about the exceptionally well-curbed SARS-CoV-2 outbreak in

Uruguay, which furthers the understanding of disease patterns and regional aspects of

the pandemic in Latin America.

Keywords: SARS-CoV-2; COVID-19 outbreak; Uruguay; South America; full genome

amplicon sequencing; spike D614G genetic mutation; phylogeographic BEAST

analysis; clinical correlations

Introduction

The novel coronavirus SARS-CoV-2, first discovered in Wuhan, China, in December 2019, rapidly extended throughout the globe, and among the >35 million confirmed positive people from >210 affected countries and territories, >1 million have died from the rapidly-spreading SARS-CoV-2 virus as of October 5th, 2020 [1].

Even though South America was mostly spared in the early months of the pandemic and was the last continent where it spread, it was severely hit with the arrival of the fall season to the Southern hemisphere. The virus is currently ravaging Latin America, with Brazil, Colombia, Argentina, Peru, and Mexico among the ten countries with the highest numbers of cases worldwide. In contrast, Uruguay, a small country located south of Brazil, has succeeded in maintaining a very low number of total cases (2,145) through the closing of its borders, a partial lockdown, and an early Test, Trace and Isolate (TETRIS) strategy [2]. Uruguay has a population of ~3.3 million inhabitants, of which more than a third (~1.3 million) live in the capital city of Montevideo, according to the last census in 2011 [3]. Montevideo is Uruguay's most interconnected city due to the presence of its international airport and harbor. The first positive case was officially registered on March 13th, and almost seven months later, 245,000 samples (>7% of the total population of Uruguay) had been tested. In March 2020, after the first four positive cases of SARS-CoV-2 were reported in Montevideo, the government issued a responsible voluntary quarantine in the country, involving the closure of schools, public entities, and businesses, urging the population to stay home [4]. On March 24th, land, maritime, and air borders were closed, allowing only Uruguayan citizens to enter the country [5]. As of October 5th, 2020, 2,145 patients have tested positive, 1,831 recovered, 243 are active cases, and 48 patients died [6].

Viral genome sequencing (genomic surveillance) is a powerful approach to

determine the origin of pathogen introductions into a certain location and trace and track

the virus's subsequent spread and evolution. It has been utilized to complement other

epidemiological parameters determined by testing, contact tracing and implementation

of other public health measures such as lockdowns [2,7-12].

Although preliminary phylogenetic analyses of Uruguayan SARS-CoV-2

sequences have previously been communicated on pre-print websites [2,7], there

remains a critical lack of knowledge regarding SARS-CoV-2 mutation, dispersal, and

transmission patterns, and whether statistical associations exist among viral genomic,

demographic, and clinical features. For example, a detailed phylogeographic analysis

has not been undertaken to investigate the global dispersal dynamics with respect to

Uruguay.

In the present study, we describe and build on genomic surveillance of a private

nonprofit healthcare system in Uruguay's capital, Montevideo, where SARS-CoV-2

cases have been identified since March 17th. We have sequenced and characterized 44

positive cases spanning March to late May. We build on the existing Nextstrain

framework, a broadly used and universally recognized analytical platform for the

analysis of global SARS-CoV-2 viral genome sequence data that has accumulated since

the start of the pandemic [13] to analyze newly sequenced SARS-CoV-2 genomes

sampled in Uruguay, and combine it with Bayesian Evolutionary Analysis of Sampling

Trees (BEAST).

An important aim of this study is to identify the different SARS-CoV-2

introduction events in Uruguay, located in a geographical region of the pandemic that

has been understudied so far. Specifically, we aim at (i) identifying and investigating

the importance of independent introduction events in establishing the COVID-19

epidemic in Uruguay, (ii) analyzing the spatial distribution of the resulting clades in the

capital city, Montevideo, (iii) looking for phylogenetic clusters within sampled

institutions (hospitals, nursing homes), iv) determining whether statistically significant

correlations exist among mutations, demographic, and clinical parameters.

Materials and Methods

Bioethics, sample collection & RNA extraction

The molecular lab at the Asociación Española Primera en Salud (AEPS) is a

fully accredited clinical lab, regulated by the Uruguayan Ministry of Health (Ministerio

de Salud Púbica, MSP). Sampling was done according to the regional IRB guidelines

and the recommendations of the MSP. Our study was evaluated by the commission of

bioethics and ethics in research of the AEPS, headed by Fernando García [14-16]. IRB

approval was waived, because the genetic analysis was restricted to the virus and not the

host, and clinical correlation analyses were done on fully de-identified samples (UY ID

and GISAID IDs were given by the Uruguayan and New York research teams,

respectively, and are not traceable to any medical record number). The participants

provided informed oral consent, and the data were analyzed anonymously. For

participants <18 years of age, formal written or verbal consent was obtained from the

parent/guardian at sampling, and data were kept anonymously for the entire study. The

molecular clinical lab at AEPS is accredited for diagnostic RT-PCR tests for SARS-

CoV-2 (COVID-19) in Uruguay. Naso-oropharyngeal swabs were collected in viral

transport media and RNA was extracted using the QIAsymphony⍰ DSP Virus/Pathogen

Mini or Midi kit (Qiagen), respectively, and confirmatory qualitative commercial RT-

PCR kits were used for diagnosis and screening (depending on critical availability

during the outbreak) (**Table 1**). Full details in **Supplemental Methods**.

Table 1. Overview of three different SARS CoV2 detection kits included in this study

Real-time RT-PCR System	Country	Regulatory Status	Target Gene(s)	Limit of Detection (copies/reaction)	Run Time (hours)	PCR Machine
LightMix Modular SARS and Wuhan CoV E/RdRp/N-gene (TIB MOLBIOL)	Germany	RUO	E, N and RdRp	5-10	1.2	LightCycler® z480 System, ROCHE
GeneFinder COVID-19 Plus Real Amp Kit (Healthcare)	Korea	HealthCanada BrazilANVISA SingaporeHSA CE-IVD	E, N and RdRp	10	2.2	CFX96 Touch Real-Time PCR Detection System, BIO-RAD
RealStar SARS- CoV-2RT-PCR kit 1.0 (Altona)	Germany	US FDAEUA CE-IVD	E, S	NA	2.25	CFX96 Touch Real-Time PCR Detection System, BIO-RAD

143   *Library Preparation, Sequencing, and Read Processing*

144   To amplify the viral genomes in preparation for sequencing, we used the Swift

Normalase Amplicon Panel (SNAP) SARS-CoV-2 Panel (Swift Biosciences, Whole

viral genome single tube NGS assay, cat# SN-5XCOV296). The libraries were run on

an Illumina NovaSeq 6000 300 cycle flow cell, as paid end 150, using dual indices.

Both positive and negative control samples were also run during library prep but not

sequenced. The negative control sample was water, and the positive control sample

consisted of SARS-CoV-2 genome (Twist Biosciences, cat# 102024) serially diluted to

100 viral copies mixed into 50 ng of Universal Human Reference RNA (Agilent, cat#

18091050). Sequencing reads were demultiplexed with Illumina bcl2fastq v2.20

requiring a perfect match to indexing barcode sequences, and aligned to the reference

SARS-CoV-2 genome (NC_045512.2, wuhCor1). Only samples with >23,000 bp

unmasked sequences were further analyzed, and variants were called using bcftools

v1.9. Details of the library generation and sequencing read processing are in the

Supplemental Methods.

Statistics

D'Agostino & Pearson normality tests were performed to assess whether data

values followed Gaussian distribution and whether parametric or nonparametric

statistical tests were indicated (GraphPad Prism v.8). As a result, correlation analyses

were done using nonparametric Spearman rank tests. Correlation coefficients (*r*), *P*-

values, adjusted *P*-values, and *q* values were calculated in Prism. *P*-values were

adjusted for multiple comparisons using Holm-Sidak ($\alpha = 0.05$). The false discovery

rate (FDR) of q was calculated at 0.5%, 1% and 5%. Correlation analyses with a sample

size of 44 had 80.7% power ($\alpha = 0.05$) to distinguish correlation coefficients that differ

by 0.4 standard deviation units (G*Power 3.1.9.4).

Genetic analysis

Sequence retrieval and multiple sequence alignment. SARS-CoV-2 reference

sequences were downloaded from GISAID EpiCoV and combined with our Uruguayan

study sequences in MEGA v.5.2 software, also used for sequence quality analysis,

capping, and data refinement, if applicable [17]. Sequence alignments were performed

using MAFFT v7.471, FFT-NS-2 method [18]. Highlighter analyses were performed on

MAFFT-aligned full SARS-CoV-2 sequences from our Uruguayan study cohort with

reference sequence Wuhan-Hu-1 as a master using the Highlighter tool provided by the

Los Alamos HIV sequence database [19].

Inference of a time-scaled phylogeny

To infer our SARS-CoV-2 time-scaled phylogenetic tree, we selected global

reference sequences used for the Nextstrain analysis specific for South America as of

August 6th, 2020. This dataset consisted of 1747 sequences sampled between December

26th, 2019 and July 17th, 2020, from Africa (40), Asia (194), Europe (112), North

America (45), Oceania (17), and South America (128). We added 74 SARS-CoV-2

Uruguayan sequences to generate an initial dataset containing 1821 viral whole-genome

sequences (Table S2). Using the Nextstrain metadata to identify the accessions of

interest, we then downloaded the latest whole-genome sequence alignment from the

GISAID database.

We aligned the whole genome sequences using MAFFT v7.471 [18] and

manually edited these by trimming the 5'and 3' untranslated regions and removing any

gap only sites and low-quality sequences. This resulted in one low-quality Uruguayan

sequence being removed, and a total of 73 remaining. The manually-edited alignment

was then used to construct a maximum likelihood tree with ultra-fast bootstraps of 1000

replicates in IQ-TREE version 2.0.3 [20], using the GTR+F+I nucleotide substitution

model selected by Bayesian information criterion using model test implemented in IQ-

TREE. TempEst [21] was used to check for outlier sequences in the tree resulting in the

removal of a further ten sequences, to make up a final data set of 1810 sequences. The

tree was dated using TreeTime version 0.7.6 [22], specifying a clock rate of 8 x 10-4

substitutions per site per year to replicate the original Nextstrain workflow analysis as

faithfully as possible.

Phylogeography analyses

To obtain an estimate of the number of independent introductions of SARS-

CoV-2 into Uruguay, we performed a preliminary phylogeography analysis using the

asymmetric rates discrete diffusion model implemented in BEAST version 1.10.4 [23],

adopting the fixed tree approach [11]. This approach greatly reduces the computational

time required to perform the analyses by annotating the phylogeography analyses onto a

fixed time-scaled phylogenetic tree. Our model considered two discrete ancestral

location states, i.e., Uruguay and non-Uruguay, and specified a Markov chain Monte-

Carlo (MCMC) length of 1 million steps, sampling every 200 steps to produce a

posterior distribution of trees containing 5,000 trees. The time-scaled maximum clade

credibility tree (MCC) tree from the discrete model phylogeography analysis conducted

in BEAST was then identified using TreeAnnotator, available as part of the BEAST

package and visualized in FigTree v.1.4.4 [24]. The BEAST log files were inspected for

convergence using Tracer version 1.7.1 [25]. All model parameters achieved effective

sample size (ESS) values >200 indicating sufficient mixing and convergence to

stationary.

To estimate the potential regional source(s) of the independent introductions into

Uruguay, we then replicated this phylogeography analysis, but this time considered

seven discrete ancestral location states, including Uruguay, Africa, South America,

North America, Oceania, Asia, and Europe.

Software Scripts and Visualization

See Supplemental Methods.

Results

Study population and clinical parameters

A total of 44 diagnosed positive COVID-19 participants were included in this

study, 25 men and 19 women with a comparable mean age (and range) of 54 (15-92)

and 59 (24-89) years, respectively. Sixty eight percent of the participants did not require

hospitalization, 18% were hospitalized or received in-home care (9% on ventilation and

5% on ICU), and 14% were deceased. Whereas the early COVID-19 positive cases in

March were predominantly clade S infections, clade G viruses subsequently became

dominant in April and May 2020. **(Figure 1 A-C)**.

Our cohort's cases came from 15 neighborhoods in the capital, Montevideo. The

majority of the samples came from the central neighborhoods of Cordón and Pocitos,

where the two biggest outbreaks within our cohort occurred (**Figure 1B and Figure**

S1). Only two participants (from the Montevideo neighborhoods Pocitos and Prado)

reported a possibility of travel-related infection after returning from Japan.

Diverse SARS-CoV-2 mutation profiles with increased prevalence of spike D614G

variants and associated mutations in the evolving epidemic

The SARS-CoV-2 genetic variants in our study group are very diverse and

comprise sequences from clades S, V, G, GH, and GR (**Figures 1A and 2A, Table S1**).

We found 446 mutations in our Uruguayan study sequences compared to the reference

Wuhan.Hu.1 sequence [26], including three gaps. 313 were SNPs (non-amino acid

changing), scattered across 60 positions, and 130 were amino acid-changing, scattered

across 32 positions of the open reading frames (**Figure 2A, B**). We observed between 5-

12 single nucleotide polymorphisms (SNP) resulting in 1-7 amino acid (AA)

replacements per viral genome (**Figure 2B, Figures S2 and S3**). In chronologically

sorted mutation/highlighter plots, various mutation patterns appeared in the first 2/3 of

the study period, whereas in the last 1/3, the mutation patterns became more

homogenous. In March and early April, ORF8 mutation L84S and the associated

C8782T single nucleotide polymorphism (SNP) were most abundant (>1/3 of

sequences) (**Figure 2A, C, Figures S2 and S3**). Both mutations have become known as

clade S-defining mutations (mostly in sublineage A.5) [27]. In addition, we found three

more SNPs to be significantly associated, namely C17470T, C25521T, and C26088T

that all together build a strongly significant, positive correlation cluster composed of

five mutations (**Figure S4**). Interestingly, after April, most sequences belonged to clade

G (sublineage B.1), defined by the spike protein's D614G mutation. 57% of our

cohort's sequences contain the D614G mutation co-occurring with SNPs C241T,

C3037T, and C14408T, the latter causing the AA replacement P323L in the RNA-

dependent RNA polymerase (RdRP) gene of nsp12 (**Figure 2A, C, Figures S2 and S4**).

As known from other global studies [27], clade S and G-associated mutations are

largely exclusive, resulting in strongly inverse correlation clusters (**Figure S4**).

Phylogenetic assessment of the regional SARS-CoV-2 outbreak

To determine phylogenetic and epidemiologic characteristics of the Uruguayan

SARS-CoV-2 outbreak, we performed a comprehensive set of phylogenetic analyses,

including maximum-likelihood trees, haplotype networks, Nextstrain-based

phylogenetic placements, and Bayesian phylogeographic analyses using BEAST

(**Figures 3 and 4, Figures S5-S8**). Focusing on all available Uruguayan SARS-CoV-2

sequences that passed our internal and GISAID's quality assessment (n=73), we

observed an intermixing of our (44) and other (29) Uruguayan study sequences, both in

maximum-likelihood IQ trees and in genetic-distance-based haplotype networks

(**Figure S5**). Consistent with the mutational analysis of our internal data set (**Figure 2**),

the phylogenetic analysis of the publicly available Uruguayan sequences reveals a

predominance of clades S and G (G, GH, and GR), the former occupying most of the

upper half of the maximum-likelihood tree (**Figure S5A**) and the right half of the

haplotype network (**Figure S5B**), the latter the respective opposite halves, highlighted

by green and red arrows for spike D614G and ORF8 L84S key mutations, respectively.

The allocation of neighborhood data on the phylogenetic tree indicated regionally

clustered appearances of phylogenetically related viruses, as most evident for Carrasco,

Pocitos, Malvin, Reducto (all in Montevideo), and Rivera (**Figure S5A**).

Phylogeographic BEAST analysis reveals 23 introductions into Uruguay mostly from

surrounding South American countries, resulting in five clusters

To assess global introductions and the regional spread of SARS-CoV-2 in

Uruguay, we performed discrete phylogeographic analysis using BEAST with all 73

Uruguayan sequences, complemented with 1737 global reference sequences, based on

the global subsampling dataset suggested by Nextstrain (**Table S2**). Genetic distance-

based haplotype networks indicated genetic relationships of Uruguayan sequences with

those from other South American countries, Europe and Asia (**Figure S6**).

By explicitly considering the time and sampling locations of our sequences,

BEAST analyses revealed further important details about the evolutionary relationships

of our sequences. The time-scaled maximum clade credibility tree (MCC) generated by

the discrete phylogeographic analysis of our 1810 SARS-CoV-2 sequences is presented

in **Figure S7** and shows a minimum of 23 independent introductions of the SARS-CoV-

2 virus occurred. Collectively, these introduction events included representatives from

seven of the GISAID clades (G, GH, GR, L, O, S and V) circulating worldwide and all

were imported to the capital city Montevideo with the exception of one imported to

Rivera.

The results of the discrete phylogeography analysis we performed that

considered seven ancestral state locations further revealed that 18 of the 23 independent

introductions are inferred to have originated from other South American countries. The

remainder include two independent introductions of GISAID clade GR viruses from

Asia, two from North America, and one clade V virus from Oceania (**Figure 3**). The

viral sequences from the only two participants in our cohort that reported a possibility

of travel-related infection after returning from Japan are inferred to have been imported

from Asia and grouped on the tree within separate clades of Asian sequences. The

estimated time to the most recent common ancestor (TMRCA), represented by the age

of the root node of the entire tree, is in mid-December 2019 (9th-21st of December),

which is in agreement with the estimated origin of the pandemic in the Hubei Province

in China, sometime between October and December, and the first contracted case in

China recorded in mid-November [28-31].

Only five of the 23 independent virus introductions into Uruguay resulted in

monophyletic clades with more than two sampled sequences in the country. These

clades comprised 21, 18, 5, 4, and 3 sequences, respectively (**Figures 3 and 4, Figure**

S8), suggesting that these viral outbreaks were maintained by community transmission

once introduced into Montevideo.

To investigate the timing of the introduction of the viruses that founded these

five main clades circulating in Montevideo, we estimated the time of their most recent

common ancestor (TMRCA), acknowledging that the actual introduction events likely

occurred even before the corresponding TMRCAs.

The TMRCA of the first main clade of 21 sampled sequences, highlighted in red

in **Figure 4**, was estimated to fall between the 2nd and 5th of March, 2020 and involved

the importation of a GISAID clade S virus. Viruses within this transmission cluster

were restricted to Montevideo, where they were distributed among nine of the local

neighborhoods, including two Hospitals and one research institute (**Figure S8**). A North

American sequence from Mexico was positioned basally to this clade on the tree

identifying this country as the most plausible source location.

The TMRCA of the second main clade, which comprised of 18 virus sequences,

highlighted in yellow in **Figure 4**, was estimated to fall between the 13th and 17th March

2020 and involved the import of a GISAID clade G virus. Viruses within this

transmission cluster were restricted to the city of Montevideo, where they were

distributed among nine neighborhoods and included samples from two nursing homes

and one hospital (**Figure S8**). The viral sequences in this clade were inferred to have a

South American origin.

The TMRCA of the third main clade of five sampled sequences, highlighted in

blue in **Figure 4** and corresponding to a GISAID clade GR, was estimated to fall

between March 20th and May 26th, 2020. This transmission cluster consisted of five

viruses from the Hospital de Rivera in Rivera, a small city situated on the border with

Brazil (**Figure S8**). This clade was inferred to have originated in South America and

groups with a sequence from Brazil on the MCC tree suggesting this was the source

location for this viral introduction

The TMRCA of the fourth main clade with four sampled sequences, highlighted

in purple in **Figure 4**, was estimated to fall between March 14th and May 20th, 2020 and

involved the introduction of a GISAID clade G virus into Montevideo (**Figure 4**). This

clade comprised four viruses from within two Montevideo neighborhoods (**Figure S8**).

The virus responsible for this introduction was also inferred to have originated in South

America.

The TMRCA of the fifth main clade of three sequences, highlighted in green in

Figure 4, was estimated to have occurred between 22nd and the 24th March 2019 and

involved the introduction of a GISAID clade GR virus into Montevideo. This clade

comprised three viruses from within a single Montevideo neighborhood (**Figure S8**).

Collectively, sequences from the four main clades described above were sampled

between March and May 2020 and were distributed among 17 of the 57 neighborhoods

or *barrios* in Montevideo.

360    All of these five independent introduction events that formed sustained

transmission chains identified here were estimated to have occurred close to the time of

the first officially diagnosed case in Uruguay on March 13th, 2020 and the putative date

of origin of the pandemic in Uruguay on March 7th, which was thought to be introduced

by a single female traveler who arrived in Montevideo on a flight from Italy and

subsequently attended a wedding reception in the city that was attended by over 500

guests.

Distribution of SARS-CoV-2 within Uruguay

369    Within these five clades we identified a total of ten sequence clusters (sequences

from the same institution that group together on the tree), spread across six of the seven

health institutions from which we had more than one sample (**Figure S8**). These

included one cluster of five GISAID clade GR sequences in the Hospital de Rivera (red

dots), two clusters of two clade G sequences in the Hospital Vilardebó (green dots),

three clusters each comprised of two clade S sequences in the Institut Pasteur (brown

dots), and two clusters from the Asociación Española Primera en Salud (blue dots)

comprising two S and two G clade sequences (**Figure S8**).

Clinical correlations separate from mutational correlation clusters

379   The availability of study participants' clinical and demographic data combined

with mutational data of the infecting SARS-CoV-2 viruses enabled us to perform

comprehensive correlation analyses (**Figures 5 and 6, Figures S9-S11**). Overall,

Spearman rank correlation analyses revealed six prominent correlation clusters of

significant positive or mixed correlations (**Figure 5, Figure S9**). Four of the highlighted

clusters in **Figure 5** (clusters 1-4) are dominated by mutations that form mixed clusters

with demographic parameters such as sampling location or treating healthcare

institution and a few other parameters. Clusters 5 and 6 are different in forming separate

clinical correlation clusters together with the parameters "sex" (cluster 5) or "age"

(cluster 6) without essential associations to virus mutations. Cluster 5 reveals a

significant association of female sex with clinically asymptomatic courses of the disease

and a lower risk of developing fever. Cluster 6 indicates a network of positive

correlations among age, lethal outcome, and five clinical parameters. In addition to the

highlighted clusters, we observed some smaller clusters, mainly composed of mutations.

The tight network of positive clinical correlations and a more outspread correlation

network of clades with regional appearances and selected demographic parameters are

shown in greater detail in **Figure 6A**. Specifically, statistical analyses of lethal outcome

as study parameter revealed significant positive correlations with arterial hypertension

(AHT), kidney failure and ICU admission complemented by borderline-significant

associations with additional clinical parameters (hospitalization, diabetes mellitus II,

and obesity) and age, but no association with any specific mutation (**Figure 6B, Figure**

S10). Accordingly, the spike D614G mutation and clade G-related viruses, in

consequence, are not associated with any clinical parameters, severity or lethality.

D614G only correlates with co-occurring/inversely occurring mutations, treating

healthcare institutions, and time since sampling started (**Figure 6C, Figure S11**).

Fatality rates among clade G, GR, and S-infected individuals were comparable at 18%

(3/17), 14% (1/7), and 12% (2/17), respectively.

Discussion

The Uruguayan epidemic is characterized by an early clade S dominance that

was subsequently replaced by clade G variants (**Figures 1 and 2**), which matches the

global trend [27,32,33]. Uruguayan clade S viruses are characterized by the key

mutations T28144C, causing the AA replacement L84S in ORF8, and C8782T, in

agreement with global clade S strains [27]. In our data set, we observed three additional

co-occurring SNPs in ORF1b and ORF3 that were present in 15 out of 17 clade S

variants, i.e., C17470T, C25521T, and C26088T. These mutations are less common and

are presumably characteristic of the regional outbreak. Further studies need to show

whether this subclade will be fixed in regional and/or supraregional epidemics, and

whether founder effects or functional features accounted for the early clade S

dominance over the original clade as well as the subsequent fluctuating prevalence and

decline. According to the CoV-GLUE database, ORF8 L84S is the 8th most prevalent

AA replacement to date [34]. After a controversial debate about the ancestry of L and S

types and the functional impact of L84S [35-38], the still limited amount of data

indicates that L84S might confer selection advantage and render the virus more virulent

based on destabilizing the immuno- and replication-modulatory protein ORF8 and

mitigating binding of ORF8 to human complement C3b [35,37-39].

End of March/early April 2020, we observed a subsequent switch in dominance

from clade S to clade G-variants (G, GR, and GH) (**Figures 1 and 2**). It positioned

Uruguay somewhere in the middle in the asynchronous transition process from spike

D614 to G614 virus predominance, i.e., between the early European and the mostly late

Asian countries [32,33]. Diverse structural and functional assays strongly suggest that

the spike D614G mutation renders SARS-CoV-2 more infectious by stabilizing its

structure, i.e., through impact on the, compared to SARS-CoV-1, even more fragile

metastable SARS-CoV-2 spike protein, thus reducing the shedding of the S1 subunit.

Furthermore, D614G triggers higher spike numbers on the virion surface and induces a

more open, receptor-binding domain (RBD)-up spike conformation toward a receptor-

binding and fusion-competent state [33,35,37,40-44]. In D614G spikes, binding to the

angiotensin-converting enzyme 2 (ACE2) receptor is not increased, and SARS-CoV-2

viruses do not acquire D614G escape mutations *in vitro* under neutralizing antibody

immune pressure [40,45]. Instead, D614G increases neutralization susceptibility of

SARS-CoV-2, which assures high sensitivity to vaccination-induced neutralizing

antibodies [46,47].

Although D614G serves as the clade G-defining mutation with likely effects on

virus infectivity/transmissibility, D614G is governed by a very strict co-appearance with

C241T, C3037T, and C14408T, both in Uruguayan and global G variants (**Figure 5,**

Figure S5) [27]. Notably, in addition to the D614G-causing A23403G mutation in

spike, C14408T is responsible for the AA replacement P323L in the RdRp gene. Based

on their central roles in viral entry and replication, their co-evolution is of particular

interest, and a mutual contribution to the selective advantage of G-haplotypes is

assumed [33]. Interestingly, none of the viruses harboring a single clade G mutation

prevailed to achieve epidemiological relevance, e.g., D614G alone or P323L alone have

≤0.3 global prevalence, whereas D614G and P323L together have ~70% global

prevalence as of August 2020 [33]. P323L, although not located in the active center,

possibly influences RdRp fidelity through allosteric effects at the nsp12 interface with

the nsp8 cofactor and might increase the viral mutation rate [33,39,48]. Thus, the

strong correlation patterns between key mutations in our Uruguayan data set, mirroring

global patterns, allows us hypothesize that coupled mutations, such as D614G in spike

and P3233L in RdRp might synergize for the epidemiological success of the virus. It

may allow a fine balance between efficient transmission (e.g., by D614G, even in

asymptomatic cases) and limited clinical presentation (e.g., by P323L, decreasing the

production of viral RNA) to eventually attenuate an aggressive virus that, as shown for

MERS and SARS-CoV-1, is more vulnerable to viral clearance with lack of long-term

epidemiological success. Further studies are needed to determine how the increasing

diversity of mutation patterns influence the fitness and reproduction of viral

populations, the susceptibility/evasion to immune responses and treatment, and how

these mutations are selected in the human body or during transmission.

Beyond the functional relevance of emerging and transmitted mutations, they

serve as a fine tool to dissect population phylodynamics, transmission chains and

epidemiologic clusters. The number of independent introduction events into a particular

country as a proportion of the total number of sequences in the data set is considered a

rough measure of the relative influence of intercontinental and international travel on

the subsequent epidemiological dynamics within that country. For Uruguay, with 23

identified independent migration events out of a total of 73 viral sequences in our

dataset, this proportion is relatively low if compared to other countries such as Belgium

(331/740) [11] but higher than others like Brazil (>100/490) [8]. It possibly indicates

that the relative influence of intercontinental and international travel has been less

important in driving the dispersal dynamics of the Uruguay outbreak compared to other,

larger or more connected countries like Belgium. The town of Rivera, situated on the

border with Brazil, has been a main concern for the government and many outbreaks

occurred along the border that were rapidly brought under control. In line with our

BEAST data that suggested a single transmission from Brazil as the main source of the

Rivera infections, the first Rivera outbreak was reported to have begun when a COVID-

19-positive Uruguayan was diagnosed on May 7th, 2020. Our BEAST analysis strongly

supports the former hypothesis from the Uruguayan Government and Ministry of Health

(MSP) that a local metallurgic worker that used to travel to Brazil everyday had been

infected with SARS-CoV-2 in Brazil and introduced this strain to Rivera [49,50].

There are two main reasons for why the extent of the geographical distribution

and the density of viruses in each neighborhood within Montevideo and Rivera

responsible for the five main clades of SARS-CoV-2 circulating in Uruguay (**Figure 4,**

Figure S8) represent an underestimate of the true values of both these variables. First,

our 73 Uruguayan sequenced viral genomes represent only a relatively small fraction of

the total number of infections that occurred in the actual outbreak seeded by these

viruses, with estimates obtained from contact tracing efforts suggesting that collectively

these viruses infected at least 364 individuals [2]. Secondly, 39 (53%) of our Uruguayan

samples were either collected in hospitals (Hospital de Rivera, Asociacion Española -

AEPS, or Hospital Vilardebó) where the infected patient was treated or where the

infection was acquired, in nursing homes, or in research institutes (Institut Pasteur)

where samples were processed. In these cases, the home address of the patient samples

is not publicly available. This precluded the adoption of the continuous diffusion

phylogeography model [51] that makes use of the actual geographic coordinates of the

samples to infer the transmission links among the sampled locations in the various

Montevideo neighborhoods, and instead, limited our analysis to describing the spatial

relationships among the sampled SARS-CoV-2 sequences.

Our discrete phylogeographic analysis provided a new perspective to the

believed origin of the Uruguayan SARS-CoV-2 outbreak from overseas by a single

traveler returning from Europe [52-54]. While overall similarities of Uruguayan

sequences with European and Asian sequences were observed in mutation patterns and

genetic distance-based haplotype networks, our phylogeographic analyses using BEAST

indicate that Uruguayan introductions that resulted in outbreaks were mostly restricted

to neighboring South American countries (**Figure 3**), which stands in contrast to the

suggestions of a recent preprint article [7]. Instead, our data support the idea that the

outbreaks that were seeded after return from overseas travel, were contained

successfully through social distancing, mask wearing, rigorous testing, contact tracing,

and partial lockdown [2].

Having determined the regional SARS-CoV-2 mutation patterns and

phylogeographic spread, the question remained whether and to what extent genomic

features are coupled to demographic and/or clinical parameters. Our correlation data

revealed significant clusters of co-occurring or mutually excluding mutations with

regionally accumulated appearances of clades/mutation clusters (**Figures 4 and 5,**

Figure S5). In contrast, the large bulk of clinical parameters clustered separately

without major influence from viral mutations (**Figures 5 and 6, Figure S10**), which is

in line with a recent publication that reported no significant impact of genetic variation

on clinical outcome [55]. More specifically, we studied pairwise correlations with the

spike D614G mutation, which, because of perfectly matching mutation patterns, also

represents correlation analyses for the RdRp P323L mutation or G-related clades (G,

GR, and GH). In an FDR-adjusted analysis, the presence of D614G mutation was

coupled to other viral mutations, treatment of the infected patients in a regional

healthcare institution, and late sampling, but not to clinical parameters (**Figures 5 and**

6, Figure S11). There have been controversial reports of D614G being associated with

higher fatality rates and/or severe illness in a few data sets [56,57], whereas more recent

data suggests no correlations of D614G with clinical outcome [33], the latter supporting

our findings. Our analysis of associations with clinical parameters pointed at significant

associations between lethal outcome and arterial hypertension, kidney failure, and ICU

admission, which mirrors clinical studies on associated factors or predictors of disease

severity/progression [58,59].

In sum, our characterization of Uruguayan SARS-CoV-2 phylogenetics,

mutation patterns, and their correlation with demographic and clinical parameters did

not identify critical viral attenuations or clinical peculiarities that can primarily account

for the exceptionally well curbed regional COVID-19 epidemic [2]. It instead suggests

that socio-epidemiologic mitigation strategies managed to curtail COVID-19 to

restricted regional transmission clusters in Uruguay.

We hope that these findings contribute to define the South American COVID-19

outbreak better, to optimize and develop efficient, fast, and low-cost mitigation

strategies and diagnostic pipelines for Uruguay and other countries, and to assist

physicians dealing with strategies for this and future emerging infections.

Acknowledgments

The authors thank all participants who agreed to participate in this study and the

healthcare personnel in Uruguay for their dedication to COVID-19 patients' care. We

wish to acknowledge the support of New York University's Data Services, Bobst

Library, and, in particular, the expertise shared by Christopher Schwarz and Senior

Academic Technology Specialist Denis Rubin in software script development. We also

acknowledge the support of the NYU Langone Health High-Performance Computing

resource and the Laura and Isaac Perlmutter Cancer Center, which partially supports the

Genome Technology Center. We thank the scientists across the world who deposited

SARS-CoV-2 sequences in GISAID, especially those who deposited 29 Uruguayan

sequences that supplemented our 44 sequences. We would also like to thank Flavia

Camacho for administrative assistance.

Disclosure Statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

All the work at the Laboratorio de Biología Molecular AEPS was supported by internal funding from the Asociación Española Primera en Salud. SD is supported by the *Fonds National de la Recherche Scientifiqu*e (FNRS, Belgium). RD was partially supported by the NIH grant 1R01AI122953. AH, CM, and PZ are supported by the Genome Technology Center, and in part by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.

Contributors

VE1, AH, and RD conceived research goals, experiments, and analyses. GWH, BM, SS, VP, and RD performed formal analyses. VE1, RB, and AH acquired funding for the project. PZ, CM, VP, NM, CB, SI, MF, VP, VE2, GM, AS, FR, MN, LP, SB, and MNZ performed experiments and/or were involved in sample acquisition. BM, MM, GWH, SD, AH, and RD developed methodologies, designed, and/or implemented computer codes. VE1, GWH, MM, SD, RB, AH, and RD supervised the research activity and validated the research output. GWH, BM, SD, VP, and RD prepared figures and tables. VE1, GWH, AH, and RD wrote the manuscript. All authors reviewed and edited the manuscript.

References

583   1.   CSSE. Center for Systems Science and Engineering (CSSE) at Johns Hopkins

584   University 2020. Available from:

585   https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740

586   fd40299423467b48e9ecf6

587   2.   Moreno P, Moratorio GA, Iraola G, et al. An effective COVID-19 response in

588   South America: the Uruguayan Conundrum. medRxiv.

589   2020:2020.07.24.20161802.

590   3.   INE. Global Health Data Exchange Washington2020 [cited 2020 September 8].

591   Available from: http://ghdx.healthdata.org/organizations/national-institute-

592   statistics-uruguay

593   4.   IMPO. Decreto No. 93/020: Declaracion de Estado de Emergencia Nacional

594   Sanitaria como Consecuencia de la Pandemia Originada por el Virus COVID-19

595   (Coronavirus) Uruguay: Registro Nacional de Leyes y Decretos; 2020 [cited

596   2020 September 4]. Available from:

597   https://www.impo.com.uy/bases/decretos/93-2020

598   5.   IMPO. Decreto No. 104/020: Autorizacion del Ingreso al Pais Unicamente de

599   Ciudadanos Uruguayos y Extranjeros Residentes Provenientes del Exterior

600   Uruguay: Registro Nacional de Leyes y Decretos; 2020 [cited 2020 September

601   4]. Available from: http://www.impo.com.uy/bases/decretos/104-2020

602   6.   SNE. Visualizador de casos coronavirus COVID-19 en Uruguay 2020 [cited

603   2020 September 15]. Available from: https://www.gub.uy/sistema-nacional-

604   emergencias/pagina-embebida/visualizador-casos-coronavirus-covid-19-uruguay

7.   Salazar C, Díaz-Viraqué F, Pereira-Gómez M, et al. Multiple introductions,

regional spread and local differentiation during the first week of COVID-19

epidemic in Montevideo, Uruguay. bioRxiv. 2020:2020.05.09.086223.

8.   Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of

SARS-CoV-2 in Brazil. Science. 2020 Sep 4;369(6508):1255-1260.

9.   Maurano MT, Ramaswami S, Westby G, et al. Sequencing identifies multiple,

early introductions of SARS-CoV2 to New York City Region. medRxiv.

2020:2020.04.15.20064931.

10.   Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, et al. Introductions and

early spread of SARS-CoV-2 in the New York City area. Science. 2020 Jul

17;369(6501):297-301.

11.   Dellicour S, Durkin K, Hong SL, et al. A phylodynamic workflow to rapidly

gain insights into the dispersal history and dynamics of SARS-CoV-2 lineages.

bioRxiv. 2020:2020.05.05.078758.

12.   Lemieux J, Siddle KJ, Shaw BM, et al. Phylogenetic analysis of SARS-CoV-2

in the Boston area highlights the role of recurrent importation and

superspreading events. medRxiv. 2020:2020.08.23.20178236.

13.   Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen

evolution. Bioinformatics. 2018 Dec 1;34(23):4121-4123.

14.   PÚBLICA MDS. Decreto N° 93/020 de 13 de marzo de 2020 2020. Available

from: https://www.gub.uy/ministerio-salud-publica/sites/ministerio-salud-

publica/files/documentos/noticias/Procedimiento%20diagn%C3%B3stico%20C

ovid-19%20en%20PIAS.pdf

15.   PÚBLICA MDS. COVID-19 Vigilancia y diagnóstico laboratorial 2020.

Available from: https://www.gub.uy/ministerio-salud-publica/sites/ministerio-

salud-

publica/files/documentos/noticias/03_MSP_COVID_19_VIGILANCIA_DIAG

NOSTICO_FINAL.pdf

16.   PÚBLICA MDS. Plan Nacional de Contingencia para la Infección (COVID-19)

por el nuevo Coronavirus (SARS CoV2) 2020. Available from:

https://www.gub.uy/ministerio-salud-publica/sites/ministerio-salud-

publica/files/documentos/noticias/01_MSP_COVID_19_PLAN_NACIONAL_C

ONTINGENCIA_GESTION_RESPUESTA.pdf

17.   Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary

genetics analysis using maximum likelihood, evolutionary distance, and

maximum parsimony methods. Mol Biol Evol. 2011 Oct;28(10):2731-9.

18.   Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence

alignment, interactive sequence choice and visualization. Brief Bioinform. 2019

Jul 19;20(4):1160-1166.

19.   tools LANL. Highlighter tool 2020. Available from: http://www.hiv.lanl.gov/

20.   Nguyen LT, Schmidt HA, von Haeseler A, et al. IQ-TREE: a fast and effective

stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol

Evol. 2015 Jan;32(1):268-74.

21.   Rambaut A, Lam TT, Max Carvalho L, et al. Exploring the temporal structure of

heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol.

2016 Jan;2(1):vew007.

22.   Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood

phylodynamic analysis. Virus Evol. 2018 Jan;4(1):vex042.

23.   Suchard MA, Lemey P, Baele G, et al. Bayesian phylogenetic and phylodynamic

data integration using BEAST 1.10. Virus Evol. 2018 Jan;4(1):vey016.

24.   Rambaut A, Drummond AJ. Tracer v1.5. 2009.

25.   Rambaut A, Drummond AJ, Xie D, et al. Posterior Summarization in Bayesian

657   Phylogenetics Using Tracer 1.7. Syst Biol. 2018 Sep 1;67(5):901-904.

658   26.   Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human

659   respiratory disease in China. Nature. 2020 Mar;579(7798):265-269.

660   27.   Mercatelli D, Giorgi FM. Geographic and Genomic Distribution of SARS-CoV-

661   2 Mutations. Front Microbiol. 2020;11:1800.

662   28.   Bryner J. 1st known case of coronavirus traced back to November in China

663   2020. Available from: https://www.livescience.com/first-case-coronavirus-

664   found.html

665   29.   Nie Q, Li X, Chen W, et al. Phylogenetic and phylodynamic analyses of SARS-

666   CoV-2. Virus Res. 2020 Oct 2;287:198098.

667   30.   van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and

668   recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020 Sep;83:104351.

669   31.   Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-

670   CoV-2. Nat Med. 2020 Apr;26(4):450-452.

671   32.   Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2

672   Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell.

673   2020 Aug 20;182(4):812-827 e19.

674   33.   Ilmjärv S, Abdul F, Acosta-Gutiérrez S, et al. Epidemiologically most successful

675   SARS-CoV-2 variant: concurrent mutations in RNA-dependent RNA

676   polymerase and spike protein. medRxiv. 2020:2020.08.23.20180281.

677   34.   CoV-GLUE. CoV-GLUE - Amino acid replacements 2020. Available from:

678   http://cov-glue.cvr.gla.ac.uk/#/replacement

679   35.   Wang R, Chen J, Gao K, et al. Characterizing SARS-CoV-2 mutations in the

680   United States. Res Sq. 2020 Aug 11.

681   36.   Kim JS, Jang JH, Kim JM, et al. Genome-Wide Identification and

682   Characterization of Point Mutations in the SARS-CoV-2 Genome. Osong Public

683   Health Res Perspect. 2020 Jun;11(3):101-111.

684   37.   Liu Q, Zhao S, Hou Y, et al. Ongoing natural selection drives the evolution of

685   SARS-CoV-2 genomes. medRxiv. 2020:2020.09.07.20189860.

686   38.   Chaw SM, Tai JH, Chen SL, et al. The origin and underlying driving forces of

687   the SARS-CoV-2 outbreak. J Biomed Sci. 2020 Jun 7;27(1):73.

688   39.   Portelli S, Olshansky M, Rodrigues CHM, et al. COVID-3D: An online resource

689   to explore the structural distribution of genetic variation in SARS-CoV-2 and its

690   implication on therapeutic development. bioRxiv. 2020:2020.05.29.124610.

691   40.   Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2

692   spike protein reduces S1 shedding and increases infectivity. bioRxiv.

693   2020:2020.06.12.148726.

694   41.   Li Q, Wu J, Nie J, et al. The Impact of Mutations in SARS-CoV-2 Spike on

695   Viral Infectivity and Antigenicity. Cell. 2020 Sep 3;182(5):1284-1294 e9.

696   42.   Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and Functional Analysis

697   of the D614G SARS-CoV-2 Spike Protein Variant. bioRxiv.

698   2020:2020.07.04.187757.

699   43.   Mansbach RA, Chakraborty S, Nguyen K, et al. The SARS-CoV-2 Spike

700   Variant D614G Favors an Open Conformational State. bioRxiv.

701   2020:2020.07.26.219741.

44.   Ogawa J, Zhu W, Tonnu N, et al. The D614G mutation in the SARS-CoV2

Spike protein increases infectivity in an ACE2 receptor dependent manner.

bioRxiv. 2020:2020.07.21.214932.

45.   Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike

protein prevents rapid mutational escape seen with individual antibodies.

Science. 2020 Aug 21;369(6506):1014-1018.

46.   Weissman D, Alameh M-G, de Silva T, et al. D614G Spike Mutation Increases

SARS CoV-2 Susceptibility to Neutralization. medRxiv.

2020:2020.07.22.20159905.

47.   Sahin U, Muik A, Derhovanessian E, et al. Concurrent human antibody and T_H1

type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv.

2020:2020.07.17.20140533.

48.   Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot

spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med.

2020 Apr 22;18(1):179.

49.   LaRed21. Primer caso autóctono de COVID-19 en Rivera: Hombre se habría

contagiado en Brasil 2020. Available from:

https://www.lr21.com.uy/comunidad/1427746-primer-caso-autoctono-de-covid-

19-en-rivera-hombre-se-habria-contagiado-en-brasil

50.   Subrayado. Metalworker from Rivera, who works in Livramento, first

autochthonous case of Covid-19 2020. Available from:

https://www.subrayado.com.uy/obrero-metalurgico-rivera-que-trabaja-

livramento-primer-caso-autoctono-covid-19-n626618

51.   Lemey P, Rambaut A, Welch JJ, et al. Phylogeography takes a relaxed random

walk in continuous space and time. Mol Biol Evol. 2010 Aug;27(8):1877-85.

52. Asadu C. SOCIALDISTANCING: How one wedding guest infected 44

Uruguayans. The Cable. 2020. Available from: https://www.thecable.ng/s-o-c-i-

a-l-d-i-s-t-a-n-c-i-n-g-how-one-wedding-guest-infected-44-uruguayans

53. Núñez I. "Estuve en un casamiento con 500 personas", relató diagnosticada con

coronavirus en Uruguay. El Pais. 2020. Available from:

https://www.elpais.com.uy/informacion/salud/estuve-casamiento-personas-

relato-diagnosticada-coronavirus-uruguay.html

54. El_Observador. "Me decían que no era un caso grave", dijo una de las

uruguayas con coronavirus. El Observador. 2020. Available from:

https://www.elobservador.com.uy/nota/-me-decian-que-no-era-un-caso-grave-

dijo-una-de-las-uruguayas-con-coronavirus-2020313194329

55. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical

outcome of COVID-19. Nature. 2020 Jul;583(7816):437-440.

56. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits

higher case fatality rate. Int J Clin Pract. 2020 May 6:e13525.

57. Toyoshima Y, Nemoto K, Matsumoto S, et al. SARS-CoV-2 genomic variations

associated with mortality rate of COVID-19. J Hum Genet. 2020 Jul 22.

58. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission

and critical illness among 5279 people with coronavirus disease 2019 in New

York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.

59. Perez-Guzman PN, Daunt A, Mukherjee S, et al. Clinical characteristics and

predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic

London NHS Trust: a retrospective cohort study. Clin Infect Dis. 2020 Aug 7.

Figure 1. Virologic, demographic, and clinical parameters of the Uruguayan study

cohort. **(A)** SARS-CoV-2 clade distribution over the ~3 month study period from

March to May. **(B)** Demographic, virologic, and sample collection data are shown in a

multicategorical alluvial diagram with the display of relatedness among features of two

neighboring nodes. **(C)** Clinical parameters of study participants, shown in alluvial

representation as in B.

Figure 2. SARS-CoV-2 mutation patterns over time and mutation hotspots along

the genome. **(A)** Highlighter plot showing mutations (mut) of Uruguayan study

sequences compared to the reference Wuhan.Hu.1 sequence as master (on top).

Mutations are shown as ticks, color-coded according to the legend to the right. Study

sequences are sorted along the y-axis according to sampling time, with the earliest

sequences on top and most recent sequences at the bottom. A SARS-CoV-2 genome

map with the three reading frames' coding genes is shown for orientation on top. All

single-nucleotide polymorphisms (SNPs) are summarized in orange, and all SNPs

resulting in amino acid (AA) replacements are summarized in blue at the bottom of the

plot at the respective alignment positions. SNPs that are prevalent in >30% of study

sequences are highlighted by orange or blue (if AA replacement) diamonds on top of

the plot. **(B)** Mirror bar chart summarizing the number of SNPs (orange) and AA

replacements (blue) per study sample, aligned with the study sample IDs in A. (C)

Lollipop plot summarizing the frequency of SARS-CoV-2 mutations in the Uruguayan

study cohort (n=44), using the same color code as in B. A SARS-CoV-2 genome map

with base-pair positions is shown at the bottom. The bubbles' y-coordinates indicate

mutation frequencies, which are also shown inside the bubbles for mutations with >10%

prevalence. Mutation details are shown in orange (SNPs, bp mutation) or blue and black

(AA replacements, bp mutation and aa mutation/affected protein region) for mutations

>30% prevalence.

Figure 3. Time-scaled phylogenetic tree to identify the source regions of the

sequences in the imported Uruguayan clusters. We employed a discrete state

phylogeography diffusion model in BEAST with seven ancestral location states (Africa,

Asia, Europe, North America, Oceania, South America, and Uruguay) to identify the

most probable source locations for the sequences in the 23 previously identified

international introductions into Uruguay. The branches of the trees are color-coded

according to each geographic region. A color gradient along the branches indicates

historic introduction events between locations. The introductions into Uruguay are

highlighted by black arrows and circles with consecutive numbering according to the

introduction event (color-code of circle outline: probable source continent). The times

of most recent common ancestors (TMRCAs) of Uruguayan (UY) sequences and their

sampling period are indicated as ranges along the x-axis timeline. Branches that are not

involved in introduction events are collapsed to facilitate visualization. The introduction

of the spike D614G mutation is indicated by a red arrowhead. The two major

Uruguayan clades are highlighted by brackets, and GISAID clades are indicated.

Figure 4. Visualization of the evolutionary relationships and spatial distribution of

SARS-CoV-2 samples in the five Uruguayan clusters. A time-scaled maximum clade

credibility tree (MCC) was generated by the discrete phylogeographic analysis of 1810

SARS-CoV-2 genomic sequences. Uruguayan sequences are shown as colored circles,

both in the phylogenetic tree and in the Uruguayan maps. The five main Uruguayan

clusters are color-coded according to the legend (clades indicated in brackets). The

remaining Uruguayan sequences, which are based on introduction events that did not

form subsequent transmission chains within Uruguay, are shown as gray circles.

Figure 5. Correlation network analysis of virologic, demographic, and clinical

parameters among Uruguayan study samples/participants. (A) In the correlation

network plot, nodes represent clinical, demographic, laboratory, mutational, and

personal parameters, and red and blue edges represent positive and negative correlations

between connected parameters, respectively. Only significant correlations ($P<0.05$) are

displayed between parameters with at least two positive events. Edge width corresponds

to the strength of the correlation. Nodes are color-coded based on the grouping in

clinical, demographic, laboratory, mutation, or personal parameters according to the

legend to the upper right, and node size corresponds to the degree of relatedness of

correlations. The six most prominent mixed correlation clusters are encircled with

dashed lines and shown in greater detail as correlograms in the dashed boxes with

matching numbers (1-6). **(B)** In the correlograms, squares are sized and color-coded

according to the magnitude of the correlation coefficient (*r*). The color code of *r* values

is shown to the right (red colors represent positive, blue colors negative correlations

between two parameters). Asterisks indicate statistically significant correlations (*$P <$

0.05, **$P < 0.01$, ***$P < 0.005$). Correlation analysis was done using nonparametric

Spearman rank tests. MVD: Montevideo, HI: healthcare institution, ICU: intensive care

unit, AHT: arterial hypertension, DM II: diabetes mellitus type II, COPD: chronic

obstructive pulmonary disease.

Figure 6. Clade and clinical correlation analysis and study parameters associated

with lethal outcome and spike D614G mutation. (A) In the edge bundling correlation

plot, red and blue edges represent positive and negative correlations between connected

parameters, respectively. Only significant correlations ($P<0.05$) are displayed, and all

parameters have at least two positive events. Nodes are color-coded based on the

grouping into clades, clinical, laboratory, neighborhood, and personal data according to

the legend at the bottom. Node size corresponds to the degree of relatedness of

correlations. Surrounding circle segments highlight a strong clinical cluster and a less

pronounced clade/sampling location cluster. **(B)** Volcano plot of parameters associated

with lethal outcome. The full data set (see **Figure 5** and **Figure S9**) was screened for

parameters with false discovery rates (FDR) of $q<0.01$ (red, considered significant) and

$0.01<q<0.05$ (pale red, considered borderline significant). **(C)** Volcano plot of

parameters associated with the presence of D614G mutation in spike proteins of study

participants' infecting SARS-CoV-2 viruses. The same display was used as in B.

Correlation analysis was done using nonparametric Spearman rank tests. All parameters

that achieved $P < 0.05$ correlations are labeled. Parameters inheriting the same dot are

boxed. MVD: Montevideo, HI: healthcare institution.

Supporting Information

Table S1. Study samples, demographic, and clinical parameters of COVID-19 participants.

Abbreviations: GF: GeneFinder, na: not available, NOS_C: naso- and oropharyngeal swabs combination, TIB: TIB ROCHE, TS: tracheal secretions. hCoV-19/Uruguay/UY-NYUMC932/2020|EPI_ISL_480430|2020-04-14 was removed from analyses because of > 35% undefined base pairs (N's) in full genome sequence.

Table S2. Origin and number of global study sequences used for Bayesian analyses.

Figure S1. Map of SARS-CoV-2 sample collection in our Uruguayan study cohort.

Map of Montevideo, Uruguay, with sampling locations indicated by dots that are colored by sample numbers according to the legend to the right. Sampling density was most significant around the center of Montevideo, indicated by a gray-to-red density gradient.

Figure S2. SARS-CoV-2 amino acid replacements over time.

Highlighter plot showing amino acid (AA) replacements of Uruguayan study sequences compared to the reference Wuhan.Hu.1 sequence as master (on top). Mutations are shown as ticks, color-coded according to the legend at the bottom. Study sequences are sorted along the y-axis according to sampling time, with the earliest sequences on top and most recent sequences at the bottom. A SARS-CoV-2 genome map is shown on top with protein regions consecutively assembled as done for the AA alignment. The gray

tones of the protein bars relate to the reading frames of their coding genes. All occurring

AA replacements are summarized at the bottom of the plot (compressed). AA

replacements that are prevalent in >30% of study sequences are indicated by diamonds

on top of the plot in the color of the replacing amino acid. A bar chart is shown to the

right summarizing the number of AA replacements per study sample, aligned with the

highlighter results and sample IDs on the left.

Figure S3. Summary of SARS-CoV-2 BP and AA mutations in the cohort and per

subject.

Left: Bar diagrams showing mutation counts per site in the entire cohort. All single

nucleotide polymorphisms (SNPs) are shown on the upper left, with total counts

indicated on the y-axis and as numerical values on top of each bar. The base pair

mutations are indicated on the x-axis together with the amino acid (AA) replacement, if

applicable. On the lower left, all AA replacements are shown separately. **Right**: Bar

diagrams showing cohort-wide mutation counts per genome. SNPs are shown on the

upper right, AA replacements on the lower right. The number of mutations per genome

is listed on the x-axis, and the occurrences in the cohort on the y-axis and as numerical

values on top of each bar.

Figure S4. Uruguayan SARS-CoV-2 mutation clusters.

Correlogram of associations among mutations observed in our Uruguayan study cohort

(n=44) with squares sized and color-coded according to the magnitude of the correlation

coefficient (r). The color code of r values is shown to the right; red colors represent

positive, blue colors negative correlations between two connected parameters on the x-

and y-axes. Asterisks indicate statistically significant correlations (*$P < 0.05$, **$P <$

0.01, ***P < 0.005). The correlogram is shown with hierarchical clustering according to

the dendrogram at the bottom. The color-strip indicates gene relatedness of mutations

according to the color code in the legend. Correlation analysis was done using non-

parametric Spearman rank tests.

Figure S5. Phylogenetic and mutation network analysis of Uruguayan SARS-CoV-

2 viruses.

A. Maximum-likelihood IQ-tree of 73 Uruguayan SARS-CoV-2 sequences and

Wuhan.Hu.1 reference sequence, run with 1000 Bootstrap replications. Branch symbols

and taxa (ID colored ranges) are colored according to country and study source, as

explained in the figure legend. The introductions of key mutations are shown by red and

green triangles. For each sample, reported/estimated site of infection/sampling location

(est: estimated, hos: treating hospital), clades, and time since global outbreak are

indicated by the circular color strip around the tree according to the legend. Clustered

appearances of clades at specific sites/neighborhoods are highlighted by arrows and

labeled. **B.** Genetic distance-based haplotype network analysis of Uruguayan SARS-

CoV-2 sequences. Circles represent populations of sequences with identical mutation

patterns (haplotypes) as compared to Wuhan.Hu.1 as reference (gaps and missing data

not considered). The circles are sized and colored relative to the number and source

countries of contributing sequences, respectively. One sample ID annotates each

haplotype population representatively. Ticks on the connecting lines indicate

discriminating mutations between haplotypes. Two major branch-defining mutations are

highlighted as red and green ticks according to the legend. Red and green polygons

encircle haplotype populations carrying respective key mutations (spike D614G and

ORF8 L84S).

Figure S6. Haplotype network analyses of Uruguayan SARS-CoV-2 sequences among global reference strains.

Genetic distance-based haplotype network analysis of 73 Uruguayan SARS-CoV-2 sequences among 609 subsampled, global SARS-CoV-2 sequences. Circles represent populations of sequences with identical mutation patterns (haplotypes) as compared to Wuhan.Hu.1 as reference (gaps and missing data not considered). The circles are sized and colored relative to the number and source countries of contributing sequences, respectively. One sample ID annotates each haplotype population representatively. Ticks on the connecting lines indicate discriminating mutations between haplotypes. The node carrying the Wuhan-Hu-1 reference sequence is labeled, and haplotypes sharing the spike D614G mutation among the sequences of the reticular network are encircled by a dashed, dark red polygon. The location of major and minor clusters of Uruguayan sequences is highlighted by large and small blue arrows, respectively.

Figure S7. Time-scaled phylogenetic tree to identify Uruguayan clusters.

A cluster is defined as a phylogenetic clade corresponding to an independent introduction into Uruguay. Uruguayan sequence tree branches are colored light blue and non-Uruguayan sequence branches gray. The two main clusters are highlighted by brackets, and their GISAID clades are indicated. The introduction of the spike D614G mutation is indicated by a red arrowhead.

Figure S8. A visualization of the evolutionary relationships and spatial distribution of our SARS-CoV-2 samples in hospitals and nursing homes in Montevideo.

Time-scaled maximum clade credibility tree (MCC) generated by the discrete

phylogeographic analysis of 1810 SARS-CoV-2 sequences. According to the legend,

Uruguayan sequences are shown as colored circles both in the phylogenetic tree and in

the Uruguayan maps, color-coded based on their relationship to hospitals and nursing

homes. Samples that are not associated with a hospital or nursing home are shown as

gray circles.

Figure S9. Correlation analysis of viral, demographic, and clinical parameters of

Uruguayan study samples/participants.

Correlogram of associations among indicated parameters as present in our Uruguayan

study cohort (n=44) with squares sized and color-coded according to the magnitude of

the correlation coefficient (r). The color code of r values is shown to the right; red

colors represent positive, blue colors negative correlations between two connected

parameters on the x- and y-axes. Asterisks indicate statistically significant correlations

(*P < 0.05, **P < 0.01, ***P < 0.005). The correlogram is shown with hierarchical

clustering according to the dendrogram at the bottom. The color-strip indicates group

relatedness of parameters according to the color code in the legend. Correlation analysis

was done using nonparametric Spearman rank tests. MVD: Montevideo, HI: healthcare

institution.

Figure S10. Statistics of correlations with lethal outcome of SARS-CoV-2 infection

in our Uruguayan study cohort.

Correlation statistics between lethal outcome and virus mutations are shown on the **left**,

and between lethal outcome and clinical and demographic parameters in the **middle**. A

summary of significant correlations, according to $q<0.01$, is shown on the **upper right**.

For each correlation, correlation values r, P values, adjusted P values, and false

discovery rates (FDR) q values are displayed together with significant discovery

assessment. The distribution of P values across the data set is illustrated in a dot plot of

ranked P values in the **lower right**. All significant results are highlighted in red. MVD:

Montevideo, HI: healthcare institution, ICU: intensive care unit, AHT: arterial

hypertension, DM II: diabetes mellitus type II, COPD: chronic obstructive pulmonary

disease.

Figure S11. Statistics of correlations with D614G spike mutation in infecting

viruses of our Uruguayan study cohort.

Correlation statistics between the presence of D614G spike mutation and other SARS-

CoV-2 mutations are shown on the **left**, and between D614G spike mutation and clinical

and demographic parameters in the **middle**. A summary of significant correlations,

according to $q<0.01$, is shown on the **upper right**. For each correlation, correlation

values r, P values, adjusted P values, and false discovery rates (FDR) q values are

displayed together with assessment of significant discovery. The distribution of P

values across the data set is illustrated in a dot plot of ranked P values in the **lower**

right. All significant results are highlighted in red. MVD: Montevideo, HI: healthcare

institution, ICU: intensive care unit, AHT: arterial hypertension, DM II: diabetes

mellitus type II, COPD: chronic obstructive pulmonary disease.

●	UY main clade 1 (S)
●	UY main clade 2 (G)
●	UY main clade 3 (GR)
●	UY main clade 4 (G)
●	UY main clade 5 (GR)
●	UY other sequences
▷	Introduction of D614G (Spike)

A

2) Associations of clades and sampling locations

1) Clinical cluster

MVD_Pocitos
MVD_Cordon
MVD_Malvin
MVD_Buceo
Clade_G
Clade_GH
Clade_GR
Clade_S
Clade_V

Lethal_outcome
Obesity
ASTHMA
COPD
Kidney_failure
DM_II
AHT
Dyspnoea
Hospitalized
ICU
Cough
Temperature
asymptomatic

Sex
Age
days_since_sampling_start
cp_ct

r
0.6
0.3
0
-0.3
-0.6

group
Clade
clinics
Lab
Personal
sampling location

strength
3
4
5

B Parameters associated with lethal outcome

q value (FDR) [-log10]

q < 0.01
q < 0.05

AHT
Kidney failure
ICU
Hospitalized
Outpatient
Obesity Age
DMII
Dyspnoe
G27281T_ORF6 W27L

q < 0.01
q < 0.05

r

C Parameters associated with D614G mutation

q value (FDR) [-log10]

C8782T
T28144C_ORF8 L84S
C17470T
C25521T
C26088T
C241T
C3037T
C14408T_nsp12 P323L
days_since_sampling_start
HI_MSP
HI_AEPS A6466G
C14805T MVD_Cordon
A11338G
C13665T
G28881A_N R203K
G28882A
G28883C_N G204R

q < 0.01
q < 0.05

r